Literature DB >> 30826198

Emergency department management of patients with syncope according to the 2018 ESC guidelines: Main innovations and aspect deserving a further improvement.

Filippo Numeroso1, Gianluigi Mossini2, Giuseppe Lippi3, Gianfranco Cervellin2.   

Abstract

The approach suggested by the 2018 ESC GL is the main road for achieving the ambitious goal "zero admission for syncope". This document has in fact introduced a clear-cut distinction between syncope associated with a definite diagnosis, which shall be managed according to the underlying condition, and the really undetermined cases, which shall be managed with prognostic stratification. ESC GL also emphasize the pivotal importance of managing patients in facilities such as ED observation syncope units or outpatient syncope clinics, as a safe alternative to admission. Moreover, they provide a table of non-syncopal causes of TLOC to be excluded, indicating the clinical features distinguishing them from syncope, clearly define the indications for additional examinations to be made after the initial evaluation and include a detailed table contains features for stratifying patients as being at high- and low-risk. However, we believe that this approach could be further improved, by especially defining criteria to identify patient neither high nor low risk, to be called at "intermediate-risk", making the prognostic stratification table easier to remember and use, by clarifying the role of laboratory tests to support the clinical judgment and by defining protocol for managing patients ED observation unit.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Emergency department; Guidelines; Risk stratification; Syncope

Year:  2019        PMID: 30826198     DOI: 10.1016/j.ijcard.2019.02.021

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  1 in total

1.  [Treatment algorithm: Syncope].

Authors:  Sebastian Wolfrum; Christoph Dodt; Guido Michels; Hans-Jörg Busch
Journal:  Med Klin Intensivmed Notfmed       Date:  2021-07-27       Impact factor: 0.840

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.